TRexBio Secures $84 Million Series B for Immunology Advancements
Deal News | Nov 13, 2024 | Agent Capital LLC
TRexBio, a biotechnology company specializing in immunology, has successfully closed an $84 million Series B financing round, led by Delos Capital, with additional participation from new and existing investors including Agent Capital, Avego BioScience Capital, Eli Lilly, Pfizer Ventures, and Johnson & Johnson Innovation JJDC. The funding is earmarked for advancing TRexBio's lead candidate, TRB-061, a TNFR2 agonist, through early clinical development targeting immune-mediated diseases such as atopic dermatitis and ulcerative colitis. The initiative underscores TRexBio’s commitment to developing therapies that restore immune system balance by focusing on regulatory T cells (Tregs). TRexBio expects to initiate a Phase 1 clinical trial for TRB-061 in 2025, with aspirations to expand its therapeutic pipeline, including the development of TRB-071. The company's innovative approach has attracted notable figures to its Board of Directors, including Dr. Eric Huang of Delos Capital. TRexBio aims to lead in creating first-in-class therapies addressing significant unmet medical needs, leveraging their Deep Biology platform to map human tissue Tregs to disease processes.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- USA – The primary location relevant to the article is the USA, where TRexBio is headquartered and where significant investment activity occurs.
- South San Francisco – This is the specific location of TRexBio, indicative of the geographical context of the company's operations.
Industry
- Biotechnology – The article revolves around TRexBio, a biotechnology firm, and discusses its efforts in developing novel therapeutic solutions for autoimmune and inflammatory diseases.
- Pharmaceuticals – The investment and ongoing clinical trials relate to the pharmaceutical industry, which involves the development and commercialization of drugs.
- Venture Capital – The article highlights a Series B financing round led by venture capital firms such as Delos Capital, which is crucial to funding biotech innovations.
Financials
- $84 million – The total amount raised by TRexBio in the Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| TRexBio | Target Company | Companies | A biotechnology company specializing in immunological treatments targeting inflammatory and autoimmune diseases. |
| Delos Capital | Lead Investor | Companies | A venture capital firm focusing on life sciences, leading the $84 million Series B financing round for TRexBio. |
| Agent Capital | Investor | Companies | A participating investor in TRexBio's Series B financing round. |
| Avego BioScience Capital | Investor | Companies | New participant in the Series B financing round for TRexBio. |
| Eli Lilly and Company | Existing Investor | Companies | A significant investor in TRexBio and collaboration partner in clinical trials. |
| Pfizer Ventures | Existing Investor | Companies | A participating existing investor in TRexBio's Series B round. |
| Johnson & Johnson Innovation JJDC, Inc. | Existing Investor | Companies | Johnson & Johnson's venture capital arm, participating in TRexBio's Series B round. |
| SV Health Investors | Existing Investor | Companies | Founder and seed funder of TRexBio and participant in Series B funding. |
| Polaris Partners | Existing Investor | Companies | A participating investor in the TRexBio Series B funding. |
| Alexandria Venture Investments | Existing Investor | Companies | A participating investor in TRexBio's funding round. |
| Eric Huang | Board of Directors | People | Partner at Delos Capital and newly appointed member of TRexBio's Board of Directors. |
| Joel S. Marcus | Board of Directors | People | Executive Chairman & Founder at Alexandria Venture Investments, joins TRexBio's Board. |
| Eric Pham | Board of Directors | People | Managing Director at Avego, appointed to TRexBio's Board. |